Literature DB >> 18301198

Plasma levels of the beta chemokine regulated upon activation, normal T cell expressed, and secreted (RANTES) correlate with severe brain injury.

Kimberly Lumpkins1, Grant V Bochicchio, Bradley Zagol, Kristian Ulloa, J Marc Simard, Stacey Schaub, Walter Meyer, Thomas Scalea.   

Abstract

BACKGROUND: The expression of the beta chemokine RANTES (regulated upon activation, normal T cell expressed, and secreted) has previously been shown to be elevated after traumatic brain injury (TBI) in animal models, but it was unknown whether the plasma level of RANTES was predictive of TBI in critically injured trauma patients.
METHODS: A prospective study was conducted on 108 critically ill trauma patients. Patients were stratified by radiologic diagnosis of TBI. Severe TBI was classified as the presence of diffuse axonal injury, midline shift, or herniation based on admission head computed tomography findings. Serum levels were evaluated at admission and hospital day 7. RANTES was measured using Luminex multiplex assays.
RESULTS: Fifty-four patients with and without TBI were compared. Severe TBI was diagnosed in 23 of the 54 TBI patients (43%) and mild/moderate TBI was found in 31 (57%) patients. The mean age of the study population was 43 +/- 20 years with a mean Injury Severity Score of 29 +/- 14. There was no significant difference between groups in age, sex, and Injury Severity Score. At admission, RANTES was significantly higher in patients with severe brain injury than in non-TBI patients (mean 1,339 pg/mL vs. 708 pg/mL, p = 0.046), and there was a trend toward significance when comparing patients with severe versus mild/moderate brain injury (mean 1,339 pg/mL vs. 752 pg/mL, p = 0.069). There was no statistically significant difference on day 7.
CONCLUSIONS: RANTES was a significant early marker of severe TBI in critically injured trauma patients, consistent with animal models. Future research on the role of RANTES in the pathogenesis of human TBI is warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18301198     DOI: 10.1097/TA.0b013e318160df9b

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  21 in total

1.  Expression analysis of the early chemokine response 4 h after in vitro traumatic brain injury.

Authors:  Astrid V Fahlenkamp; Mark Coburn; Michael Czaplik; Yu-Mi Ryang; Markus Kipp; Rolf Rossaint; Cordian Beyer
Journal:  Inflamm Res       Date:  2010-11-23       Impact factor: 4.575

Review 2.  The Role of Inflammatory Mediators in the Pathogenesis of Alzheimer's Disease.

Authors:  Gholamreza Azizi; Shadi S Navabi; Ahmed Al-Shukaili; Mir H Seyedzadeh; Reza Yazdani; Abbas Mirshafiey
Journal:  Sultan Qaboos Univ Med J       Date:  2015-08-24

Review 3.  Inflammatory reaction after traumatic brain injury: therapeutic potential of targeting cell-cell communication by chemokines.

Authors:  Stefka Gyoneva; Richard M Ransohoff
Journal:  Trends Pharmacol Sci       Date:  2015-05-13       Impact factor: 14.819

Review 4.  Biomarkers in traumatic brain injury.

Authors:  Richa Sharma; Daniel T Laskowitz
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

5.  Hepatic expression of serum amyloid A1 is induced by traumatic brain injury and modulated by telmisartan.

Authors:  Sonia Villapol; Dmitry Kryndushkin; Maria G Balarezo; Ashley M Campbell; Juan M Saavedra; Frank P Shewmaker; Aviva J Symes
Journal:  Am J Pathol       Date:  2015-10       Impact factor: 4.307

6.  Local and systemic chemokine patterns in a human musculoskeletal trauma model.

Authors:  Daniel Bastian; Margareth Vislie Tamburstuen; Ståle Petter Lyngstadaas; Olav Reikerås
Journal:  Inflamm Res       Date:  2009-03-10       Impact factor: 4.575

Review 7.  Cytokines and myelination in the central nervous system.

Authors:  Thomas Schmitz; Li-Jin Chew
Journal:  ScientificWorldJournal       Date:  2008-11-02

Review 8.  Can Mesenchymal Stem Cells Act Multipotential in Traumatic Brain Injury?

Authors:  Fatemeh Dehghanian; Zahra Soltani; Mohammad Khaksari
Journal:  J Mol Neurosci       Date:  2020-01-02       Impact factor: 3.444

9.  Inhibition of miR-155 Limits Neuroinflammation and Improves Functional Recovery After Experimental Traumatic Brain Injury in Mice.

Authors:  David J Loane; Alan I Faden; Rebecca J Henry; Sarah J Doran; James P Barrett; Victoria E Meadows; Boris Sabirzhanov; Bogdan A Stoica
Journal:  Neurotherapeutics       Date:  2019-01       Impact factor: 7.620

Review 10.  Clinical evidence of inflammation driving secondary brain injury: a systematic review.

Authors:  Holly E Hinson; Susan Rowell; Martin Schreiber
Journal:  J Trauma Acute Care Surg       Date:  2015-01       Impact factor: 3.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.